GSK and the GOG Foundation began enrolling the first patient in a global Phase 3 trial testing mocertatug rezetecan in platinum-resistant ovarian cancer. The study, GOG-3132/BEHOLD-Ovarian01 (NCT07286266), compares the investigational oral therapy against standard-of-care chemotherapy, marking an escalation from earlier development into late-stage validation.